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Abstract 
Conventional methodologies to control vector borne diseases with chemical pesticides are 
often associated with environmental toxicity, adverse effects on human health and the 
emergence of insect resistance.  In the paratransgenic strategy, symbiotic or commensal 
microbes of host insects are transformed to express gene products that interfere with 
pathogen transmission.  These genetically altered microbes are re-introduced back to the 
insect where expression of the engineered molecules decreases the host’s ability to transmit 
the pathogen.  We have successfully utilized this strategy to reduce carriage rates of Trypa-
nosoma cruzi, the causative agent of Chagas disease, in the triatomine bug, Rhodnius prolixus, 
and are currently developing this methodology to control the transmission of Leishmania 
donovani by the sand fly Phlebotomus argentipes. Several effector molecules, including antimi-
crobial peptides and highly specific single chain antibodies, are currently being explored for 
their anti-parasite activities in these two systems.  In preparation for eventual field use, we are 
actively engaged in risk assessment studies addressing the issue of horizontal gene transfer 
from the modified bacteria to environmental microbes. 
Key words: Paratransgenesis, Chagas disease, triatomine bugs, visceral leishmaniasis, sand flies, 
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Introduction 
Paratransgenesis is a “Trojan Horse” approach to 
control of disease transmission. In this strategy, bac-
terial flora native to disease-transmitting vectors are 
isolated and genetically transformed in vitro to export 
molecules that interfere with pathogen transmission. 
The genetically altered symbionts are then 
re-introduced into the host vector where expression of 
engineered molecules affects the host’s ability to 
transmit the pathogen, i.e. its vector competence. This 
approach attempts to decrease pathogen transmission 
without adverse effects on vectors themselves. Fur-
ther, it employs, as a gene delivery mechanism, bac-
terial flora native to the host vector.  
 There are several requirements for such an ap-
proach to work[1]: (a) a population of symbiotic bac-
teria must exist within a given disease-transmitting 
vector (b) symbiotic bacteria should be specific to a 
given vector (c) bacterial symbionts should be ame-
nable to culture and genetic manipulation (d) genet-
ically altered symbionts should remain stable (e) fit-
ness of the genetically altered symbionts to re-infect 
host vectors should not be compromised, nor should 
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their normal symbiotic functions be altered (f) 
transgene products released from the genetically al-
tered symbionts should interact with the target path-
ogen(s) and (g) a method must exist for dispersal of 
the genetically altered symbionts amongst naturally 
occurring populations of vectors with minimal 
non-target spread of foreign genes to environmental 
bacteria and other arthropods. 
Our laboratory had pioneered the paratrans-
genic approach to control Trypanosoma cruzi trans-
mission by triatomine vectors of Chagas disease[2, 3].  
We have since applied this technique to a number of 
other arthropod systems, including sand 
fly-transmitted leishmaniasis[4] and sharpshoot-
er-mediated Pierce’s disease of grapes[5].  We are 
further developing a modification of this procedure to 
control diseases in shrimp mariculture[6].  In this re-
view, we will describe how this approach is utilized to 
impart passive immunity to arthropod vectors – tria-
tomine bugs and sand flies – to render them incom-
petent to parasitic infections.  
Chagas disease 
Chagas disease is caused by the protozoan 
Trypanosoma cruzi and is transmitted to humans by 
blood-sucking triatomine bugs. These bugs infest 
thatch and adobe of poorly constructed homes and 
transmit the parasite to humans via fecal droplets 
deposited following a bloodmeal.  This human para-
sitic disease is endemic throughout much of rural 
Mexico as well as Central and South America. In re-
cent years, human migration from these regions of the 
world has significantly changed the epidemiology of 
this disease.  Today, there are a significant number of 
people infected with T. cruzi in the United States 
(>300,000), Canada (>5,500), Europe and the Western 
Pacific (>80,000), Japan (>3,000), and Australia 
(>1,500)[7-9]. Of the 8 –11 million people infected with 
T. cruzi globally, approximately 50,000 will die each 
year[10]. Chagas disease accounts for the loss of 
500,000 disability-adjusted life-years annually, second 
only to malaria and leishmaniasis in the global cal-
culus of vector borne diseases.   
There are three successive stages of Chagas dis-
ease. The acute stage - characterized by generalized 
malaise, fever, lymphadenopathy, hepatosplenomeg-
aly - occurs shortly after infection and is minimally 
symptomatic for 4 to 8 weeks. The indeterminate 
phase can last between 10 to 20 years and is charac-
terized by paucity of clinical manifestations but active 
replication of T. cruzi and periodic release of blood-
stream forms of the parasite into the circulation. 
Decades following the primary infection, between 
10-30% of infected individuals progress to chronic 
Chagas disease. Patients develop irreversible lesions 
of the autonomous nervous system in the heart, 
esophagus, colon and the peripheral nervous sys-
tem[11, 12].  The chronic phase of Chagas disease is 
incurable and is associated with, on average, a ten 
year shortening of life span. Gastrointestinal mani-
festations of chronic Chagas disease are geograph-
ically restricted[13] and play a lesser role in the overall 
disease burden of Chagas disease.  Progressive heart 
disease, a hallmark of chronic Chagas disease, is a 
leading public health concern throughout much of 
Central and South America[14].  
 In the absence of vaccines and drug therapies, 
control of Chagas disease relies largely on measures 
aimed at vector eradication. Though screening of 
blood banks to reduce transfusion-associated Chagas 
disease is ongoing, public health measures aimed at 
interrupting vector transmission to humans in en-
demic regions have the potential to eliminate this 
devastating disease. Several large-scale insecti-
cide-based efforts have been undertaken with con-
siderable success to date. The Southern Cone Initia-
tive, a joint agreement between the governments of 
Argentina, Bolivia, Brazil, Chile, Paraguay, Uruguay 
and Peru, was launched in 1991 to control Chagas 
disease by the elimination of the main vector, Triatoma 
infestans. In some Southern Cone nations, such as 
Brazil, Uruguay and Chile, results have been dramatic 
and new cases of Chagas disease have been virtually 
eliminated[15, 16]. However, several factors raise 
concern about the re-emergence of Chagas disease in 
the Southern Cone. Reduced effectiveness of pyre-
throids in peridomestic habitats had led to the in-
complete elimination of T. infestans in several South-
ern Cone countries[17-19].  Further, several Triatom-
ine populations have been documented to develop 
resistance to a variety of insecticides in Chagas dis-
ease endemic area[20]. For these reasons, alternate 
methods aimed at controlling Chagas disease trans-
mission must be explored. 
Paratransgenic control of transmission of T. 
cruzi 
The symbiotic associations between triatomine 
vectors, specifically T. infestans and Rhodnius prolixus, 
and nocardiform actinomycetes is well character-
ized[21]. Descriptions of nocardia-like bacteria in 
colony populations of T. infestans date back to the 
mid-1900’s[22]. These bacteria are thought to aid in 
the processing of B complex vitamins in the restricted 
blood diets of the host and are essential to the survival 
of the triatomine. The widespread carriage of nocar-
diform actinomycetes by several triatomine species 
and the amenability of these bacteria to genetic ma-
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nipulation are the cornerstones of the paratransgenic 
strategies aimed at interrupting vectorial transmission 
of Trypanosoma cruzi.   
The soil-associated nocardiform actinomycete 
Rhodococcus rhodnii resides extracellularly in the gut 
lumen of R. prolixus in close proximity to T. cruzi.  This 
microbe is transmitted effectively from adult tria-
tomine bugs to their progeny through coprophagy, 
the ingestion of fecal material from other bugs. The 
vital role of R. rhodnii in the growth and development 
of R. prolixus has been demonstrated repeatedly under 
laboratory conditions. R. prolixus nymphs that lack 
gut-associated symbionts (aposymbiotic) do not reach 
the sexually mature adult stage, and most will die 
after the second developmental molt. Introduction of 
the bacteria to first or second instar nymphs permits 
normal growth and maturation. In 1992, we trans-
formed R. rhodnii with pRr1.1, a shuttle plasmid con-
taining a gene encoding resistance to the antibiotic 
thiostrepton, to support the hypothesis that a 
transgene-carrying symbiont could be introduced into 
R. prolixus.  We showed that the modified symbiont is 
maintained through the insect’s development without 
adverse effects on insect survival and fitness[23].  We 
have since developed a number of anti-trypanosomal 
molecules – antimicrobial peptides (AMP’s), recom-
binant endoglucanases that disrupt the surface of the 
parasite and functional transmission-blocking single 
chain antibodies - for expression in triatomine vectors.  
In a seminal study, we re-populated aposymbi-
otic R. prolixus nymphs with R. rhodnii transformed to 
express the AMP cecropin A[3]. These paratransgenic 
insects were then allowed to engorge on T. cruzi-laden 
human blood. At the end of the trial, 65% of the in-
sects examined had complete clearance of viable T. 
cruzi.  The remaining 35% of the bugs had substan-
tially reduced numbers of parasites, demonstrating 
that the in vivo expression of an AMP from a genet-
ically modified symbiont can significantly reduce 
carriage of the infectious parasite from the host vector.  
AMP’s are a class of peptides that are recognized as 
important components of innate cell defense mecha-
nisms[24, 25].  They are produced in insects, plants, 
and animals, are present on a variety of cellular sur-
faces, and vary considerably in primary and second-
ary structure[26]. AMP’s are amphipathic, highly 
basic molecules that can discriminate between host 
and bacterial membranes by charge and composi-
tion[26].  While most AMP’s disrupt membranes of 
non-host cells, other modes of actions, including in-
terfering with host metabolism and targeting cyto-
plasmic components have been reported[25, 27, 28].  
We recently reported on the in vitro activities of sev-
eral other AMP’s against T. cruzi.  We showed that 
apidaecin, magainin and mellittin had toxicity profiles 
that may be applicable to the Chagas paratransgenic 
system, killing T. cruzi at concentrations lower than 10 
uM and requiring greater than 100 uM to show any 
effect on R. rhodnii[29].  Further, when used in 
pair-wise combinations, these anti-microbial peptides 
resulted in much improved T. cruzi killing efficiency.  
For example, when used alone, apidaecin kills T. cruzi 
at 10 uM, but when used in combination with ce-
cropin, melittin or magainin, the concentration re-
quired for killing is decrease by 10-fold (Figure 1).  We 
have now generated strains of R. rhodnii that produce 
four different AMP’s; cecropin, apidaecin, melittin 
and magainin.  Lysates from these cells are biologi-
cally active against T. cruzi (Fieck et al, in prep).  Work 
is currently in progress to introduce these trans-
formants either individually, or in combination, into 
aposymbiotic triatomine nymphs.  Based on our in 
vitro data (Fieck et al, in prep), we would expect close 
to 100% clearance of T. cruzi following challenge. 
A number of other anti-trypanosomal molecules 
are currently being assessed for expression in R. rhod-
nii. One such molecule is 1,3-glucanase. The surface 
of T. cruzi is covered by a thick coat of glycoconju-
gates, the major component of which is a family of 
mucin-like glycoproteins. These glycoconjugates are 
required by the parasites for attachment, and subse-
quent infection, in the hindgut of the triatomine vec-
tor[30]. In unpublished work, we had shown that Ar-
throbacter luteus lyticase, an endoglucanases complex 
consisting of 1,3-glucanase and alkaline proteases, is 
very efficient in lysing T. cruzi in vitro, and is non-toxic 
to R. prolixus. We recently inserted the cDNA encod-
ing Arthrobacter luteus -1,3-glucanase into pRrExpA, 
our E. coli/R. rhodnii shuttle vector.  Recombinant 
-1,3-glucanse is biologically active, and clears T. cruzi 
at low concentrations (Jose et al, in prep), suggesting 
that it could potentially be used as another effector 
molecule for the paratransgenic control of Chagas 
disease.   
Competence of the triatomine vector to transmit 
T. cruzi depends in part on parasite maturation in the 
insect gut.  This maturation process, also known as 
metacyclogenesis or the transformation from nonin-
fective epimastigotes into metacyclic trypomastigotes, 
is dependent in part on interactions between surface 
epitopes of T. cruzi and the gut lumen of the triatom-
ine bug. These interactions could therefore be a po-
tential target for paratransgenic expression of anti-
body fragments.  Recombinant single chain antibodies 
(scFv) are fusion proteins containing the variable re-
gions of the heavy and light chains of immunoglobu-
lins. These regions are connected to one another with 
a short linker of about 10 amino acid residues.  De-
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spite the absence of the constant regions, these pro-
teins retain specificity to target antigens comparable 
to that of parent immunoglobulins.  Because of their 
small size, scFv’s are readily produced in bacterial 
cultures. In previous work, we genetically modified R. 
rhodnii to produce a functional murine three-domain 
antibody fragment (rDB3) that binds 
progesterone[31]. The scFv-producing cells were 
subsequently fed to aposymbiotic R. prolixus.  We 
showed that the rDB3 antibody fragment was synthe-
sized and secreted into the insect gut lumen by the 
engineered symbiont in a stable fashion over the 
6-month period of the study. We later repeated these 
studies via the successful transformation of a Coryne-
bacterium symbiont of T. infestans, with the same 
shuttle plasmid[32].  Recently, we reported on the 
design, assembly, production and characterization of 
two scFV’s that are tagged with intrinsic red fluores-
cent properties to the sialyl-Tn and sialyl-(le)a surface 
glycans of T. cruzi[33]. The monoclonal antibodies 
B72.3 and CA19.9 bind to the above glycans, respec-
tively.  Using these monoclonals as a template, syn-
thetic DNA sequences of B72.3 and CA19.9 antibody 
variable domains in VH–VL orientation were gener-
ated.  Instead of a standard linker, a monomeric red 
fluorescent protein (mRFP) from Discosoma was in-
serted as a rigid linker between the VH and VL do-
mains, generating a novel and highly stable REDan-
tibody. The resulting recombinant fluorescent mole-
cules were demonstrated to specifically bind to fixed 
T. cruzi epimastigotes by confocal microscopy (Figure 
2).  The ability of these molecules to bind and inacti-
vate live parasites is currently being investigated.  We 
are also in the process of subcloning genes encoding 
these novel antibodies into our shuttle vector system 
for expression in R. rhodnii.   
 
 
Figure 1: Antimicrobial peptide kill curves for dual-combination treatments of T. cruzi liquid cultures.  Results averaged 
from triplicate samples in three separate experiments and displayed as the percent change in absorbance at 600 nm 
compared to untreated controls.  Figure is adapted from Fieck et al, Trypanosoma cruzi: synergistic cytotoxicity of multiple 
amphipathic anti-microial peptides to T. cruzi and potential bacterial hosts, Exp Parasitol, 2010, 125:342-347 
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Figure 2: Confocal image of anti-sialy-Tn REDantibody targeting glycan structures on the surface of T. cruzi epimastigotes. 
Figure adapted from Markiv et al. Module based antibody engineering: a novel synthetic REDantibody. J Immunol Methods, 
2011, 364:40-49 
 
Though many triatomine vectors of T. cruzi exist, 
we have focused primarily on genetically modifying 
R. rhodnii, the symbiont of R. prolixus, for paratrans-
genic purposes.   As described earlier, the paratrans-
genic approach derives from the close symbiotic as-
sociation between bacteria and arthropod vector. In 
light of this, we had examined the specificity of sym-
bionts in several triatomine vectors.  A wide variety of 
bacterial genera, including Nocardia, Corynebacteria 
and Streptococci, were isolated from the midgut of T. 
infestans[34]. In previous studies, we had identified a 
novel Corynebacterium symbiont from laboratory col-
onies of T. infestans isolated from the Gran Chaco re-
gion of Argentina[32], and studied the role of nocar-
diform actinomycetes such as Rhodococci, Nocardia 
spp, Gordonia spp, Corynebacterium spp and Tsuku-
murella [1-3, 31, 32] in a number of triatomine bugs, 
including T. dimidiata and T. sordida (Pennington and 
Durvasula, unpublished data). In all cases, we noted 
that absence of matched actinomycetes in the arthro-
pod resulted in growth arrest and death of nymphs.  
However, when introduced into the correct vector, the 
actinomycetes supported growth and sexual matura-
tion of these bugs.  These results suggest that symbi-
onts are indeed specific to their respective hosts, and 
would need to be first identified for each arthropod 
vector of T. cruzi prior to initialization of the para-
transgenic strategy. Once modified, the genetically 
altered symbiont should not impair vector survival 
and fecundity. In previous studies, we had shown 
that transformed R. rhodnii expressing either cecropin 
A or rDB3 resulted in no adverse effects on R. prolix-
us[3, 31].  The effects of apidaecin, mellitin, magainin 
and 1,3-glucanase-expressing R. rhodnii on R. prolixus 
are currently being evaluated.  Finally, since scFv’s 
bind with high specificity to sites on the surface of T. 
cruzi, we expect that they will exert minimal toxicity 
to the vector. 
In preparation for field trials, we tested the effi-
cacy of a simulated triatomine-fecal preparation, 
CRUZIGARD, consisting of an inert guar gum matrix 
dyed with India ink, as a method for delivery of en-
gineered R. rhodnii to colonies of R. prolixus.  The 
CRUZIGARD preparation was mixed with 108 
CFU/ml of transformed R. rhodnii, and used to im-
pregnate cages constructed of thatch and ado-
be-building materials from the Chagas-endemic re-
gions of Guatemala (Olopa)[35]. Adult R. prolixus 
from the Olopa district were placed in the cages and 
removed after eggs were laid. The experiments were 
conducted over a 9-month period. Genetically altered 
R. rhodnii were detected in approximately 50% of F1 
adults and comprised nearly 95% of the colony form-
ing units (CFU) in these bugs, providing evidence that 
CRUZIGARD may be useful as a gene dispersal 
strategy under conditions of microbial competition. 
To increase the likelihood of CRUZIGARD probing, 
we have on-going collaborations to develop triatom-
ine attractants and semiochemicals to supplement the 
current CRUZIGARD formulation. The addition of 
these semiochemicals is further anticipated to increase 
the volume and duration of CRUZIGARD ingestion, 
and consequently, increase rates of vector inoculation 
with transformed symbiont.  
Demonstrating vector uptake of genetically al-
tered symbionts and, ultimately, refractoriness to T. 
cruzi infection via CRUZIGARD does not suggest or 
substantiate a strategy for field delivery. A practical 
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strategy in an endemic region should specify the 
minimum amount of transformed symbionts neces-
sary to prevent T. cruzi transmission to humans, and a 
method of CRUZIGARD application suitable for 
at-risk domiciles in the endemic region. In other 
on-going studies, we are working with collaborators 
to develop a theoretical framework to assess parame-
ters such as minimum effective release of 
CRUZIGARD and inoculation of target triatomine 
population.  
We further realize that the deployment of ge-
netically altered lines of bacteria to target field popu-
lations of triatomine bugs may have profound envi-
ronmental consequences. Horizontal gene transfer, 
uptake of foreign genes by non-target arthropods and 
microbial biodiversity may all be adversely affected 
by such a strategy.  We have developed a mathemat-
ical model predicting horizontal gene transfer (HGT) 
between genetically modified R. rhodnii and G. ru-
bropertinctus.[36] The model treats HGT as a compo-
site event whose probability is determined by the joint 
probability of three independent events: gene transfer 
through the modalities of transformation, transduc-
tion, and conjugation. Genes are represented in ma-
trices, with Monte Carlo method and Markov chain 
analysis used to simulate and evaluate environmental 
conditions. The model is intended as a risk assessment 
instrument and predicts an HGT frequency of less 
than 1.14 x 10-16 per 100,000 generations at the 99% 
certainty level. This predicted transfer frequency is 
less than the estimated average mutation frequency in 
bacteria, 10-1 per gene per 1,000 generations.  This 
suggests even if HGT were to occur between R. rhodnii 
and G. rubropertinctus, the transgene would likely not 
persist in the recipient organism, and that the likeli-
hood of these unwanted events are low.  
The field release of engineered bacteria cannot 
occur until a rigorous risk assessment framework and 
regulatory apparatus are in place.  To inform the reg-
ulatory process, evaluation of the risks and benefits of 
the paratransgenic strategy are required.  Since such 
information will not readily be available through field 
release trials, we are working with several collabora-
tors to develop a framework involving rigorous 
mathematical modeling and simulations. Outputs of 
these models will be integral to informing risk as-
sessment and regulatory oversight of the paratrans-
genic program, and ultimately, to permit field trials of 
the paratransgenic strategy. 
Visceral leishmaniasis 
Leishmaniasis is a devastating neglected tropical 
disease caused by the obligate intracellular protozoa 
Leishmania donovani in India, L. infantum in Europe, 
and L. chagasi in South America. Natural transmission 
occurs through the bite of an infected sand fly of the 
genus Phlebotomus (Old World) or Lutzomyia (New 
World). This disease is present in 88 countries, af-
fecting approximately two million people per year 
with a global prevalence of 12 million with 350 million 
people at risk for infection[37].    
Visceral leishmaniasis (VL) is among the most 
neglected diseases based on dearth of research and 
notable lack of innovations in disease treatment and 
control.  It is by far the most devastating form of 
leishmaniasis, and is nearly 100% fatal if untreated. 
There are 500,000 annual new cases of VL in the 
world, one-half of which occur in India.  Bihar, the 
most affected state in India, is home to nearly 90% of 
the new cases each year[38] followed by West Bengal 
and Uttar Pradesh.  Bihar is also the region where 
approximately 95% of the mortality occurs among the 
reported VL cases in India[38]. The disease often pre-
sents as an indolent fever, malaise and wasting with 
co-existent splenomegaly, bone marrow involvement 
and hepatomegaly.  
Treatment of Visceral Leishmaniasis 
Treatment of leishmaniasis varies greatly with 
the type of disease (cutaneous, mucosal, or visceral), 
Leishmania species, and geographic location.  Old 
World cutaneous disease often self-heals and as a re-
sult requires no treatment. New World cutaneous 
disease is less likely to self-resolve and because of the 
risk of development of mucosal leishmaniasis with 
Leishmania braziliensis, systemic treatment is more 
commonly undertaken.  Treatment courses are often 
lengthy and cure is difficult to achieve with many 
cutaneous and mucocutaneous forms.  Treatment 
modalities for cutaneous leishmaniasis range from 
local therapy including topical treatments and in-
tralesional injections to systemic therapy with penta-
valent antimonials, amphotericin B or miltefosine 
being used most commonly. 
The treatment of VL has changed substantially 
over the last decade.  Pentavalent antimonial drugs 
were the standard drug of choice until the emergence 
of drug non-responsiveness in highly endemic re-
gions such as Bihar, India[39]. Newer treatment mo-
dalities, while effective, pose practical limitations as 
the majority of patients suffering from VL are unable 
to pay for costly medications and hospitalization.  
Newer therapies include multiple formulations of 
amphotericin B, paramomycin, and miltefosine.  Dose 
finding studies have suggested significant efficacy 
with even a single dose of liposomal amphotericin 
B[40], however, it is unlikely that this single-dose 
regimen will be adopted into practice because of the 
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risk of emergence of drug resistance.  Paramomycin, 
an injectable aminoglycoside medication, has also 
been studied and found effective in clinical trials[41].  
Miltefosine, an oral agent with excellent skin penetra-
tion has proven successful in treatment of VL and has 
the advantage of not requiring hospitalization for 
administration[42].   Most recently, there has been 
evaluation of combinations of drugs for the treatment 
of VL.  Combination therapy has the distinct ad-
vantage of decreasing the risk of drug resistance, de-
creasing the side effects and improving 
cost-effectiveness.  Regimens found to be effective 
include combination therapy with amphotericin B and 
miltefosine, amphotericin B and paramomycin and 
miltefosine in combination with paramomycin[43]. 
In the absence of a vaccine, control of VL has 
focused largely on vector eradication through pesti-
cide use.  Several large-scale control efforts have tar-
geted the elimination of domestic and peri-domestic 
populations of sand flies including Plebotomus argen-
tipes.  Initially, DDT spraying in India associated with 
the National Malaria Control Program in the 1960’s 
was very successful in reducing sand fly populations 
and cases of VL were nearly eliminated[44].  Howev-
er, as with triatomine vectors, recent studies show 
certain populations of sand flies gaining insecticide 
resistance[45-47], resulting in growing concern about 
insecticide use that is cost prohibitive and responsible 
for considerable environmental toxicity.  Further-
more, in many parts of Bihar and West Bengal, return 
of peri-domestic populations of sand flies has been 
observed within one year of insecticide spraying[48].  
Paratransgenic control of leishmania 
transmission 
We are developing a paratransgenic strategy to 
control transmission of L. donovani by P. argentipes.   
As in the case of Chagas disease control, we intend to 
prevent disease transmission by effectively providing 
the sand flies with passive immunity against the in-
vading parasite.  We chose to focus our paratrans-
genic efforts in Bihar, India where P. argentipes is the 
main vector for VL for several reasons. Though mul-
tiple studies have reported the difficulties in identi-
fying breeding sites of New World sandflies[49-52], 
there is substantial data attesting to identification of 
breeding sites of P. argentipes in eastern India[53-57].  
Ghosh and Bhattacharya[58] described P. argentipes 
breeding sites in West Bengal and further described 
the population biology of this vector[59].  A study in 
Pondicherry, India delineated breeding sites of both 
P. argentipes and P. papatasi[60].  In VL-endemic re-
gions of Bihar State, Kesari et al.[61] were highly suc-
cessful in isolating sand fly larvae from soil samples 
of mixed dwellings and isolated cowsheds. The accu-
racy in identifying these sites and retrieving larvae 
from the soil suggest that breeding sites of P. argenti-
pes in the endemic states of Bihar are characterized to 
some degree.  
To date, there are no known reports of any sym-
biotic bacteria associated with P. argentipes.  However, 
the gut microbiology of adult sandflies has been de-
scribed in the past[62]. In 2008, we detailed an exten-
sive analysis of the gut flora of P. argentipes trapped 
from four VL-endemic sites in Bihar, India, and con-
cluded that sand fly-microbial associations reflect the 
environment in which the sand flies reside[4]. In this 
survey, we identified 28 distinct gut microorganisms 
through 16S rDNA sequencing.  A number of these 
microbes, including Staphylococcus spp., Escherichia 
coli, and Enterobacter, are all human pathogens, 
thereby precluding their use in a paratransgenic sys-
tem.  However, we also identified an abundance of 
several nonpathogenic soil bacteria that are used in 
industry including Bacillus megaterium, Brevibacterium 
linens, Bacillus subtilis, and Bacillus pumilis. Our goal is 
to use these “generally regarded as safe” microbes as 
delivery vehicles for anti-leishmanial compounds to 
sandflies.  
How would the paratransgenic strategy work in 
this vector? The life cycle of P. argentipes is short with 
a brief window of parasite development. Female sand 
flies acquire the parasite when they ingest macro-
phages infected with amastigotes during a blood 
meal. The parasite matures within the alimentary tract 
of the sand fly as a promastigote form.  Four to five 
days after feeding, the promastigotes move forward 
to the esophagus and the salivary glands of the insect. 
When the sand fly subsequently takes a blood meal 
from the mammalian host, leishmania promastigotes 
are transferred to the host. For the paratransgenic 
strategy to be successful in this system, the recombi-
nant commensal bacteria should preferably persist 
within the sand fly gut until the first blood meal. 
However, an anti-leishmania recombinant molecule 
may remain active in the sand fly gut in the absence of 
recombinant carrier (Figure 3). In our experience with 
paratransgenic triatomine bugs, recombinant cecropin 
A persisted for over 6 months in the gut lumen with 
biological activity [3]. Such an outcome would actu-
ally be viewed as highly desirable as the intended 
biological effect would occur with reduced risk of 
unwanted spread of transgenic bacteria via activities 
of the adult flies[63].  
The acquisition of bacteria in P. argentipes has not 
been studied. However, the large number of soil and 
environmental bacteria isolated in our study suggests 
that sand flies are typically colonized by microbes 
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encountered at breeding sites or during sugar 
meals[4]. Our strategy is to deploy large concentra-
tions of transformed commensal bacteria at sand fly 
breeding sites to selectively colonize the emerging 
flies. We recently demonstrated the transstadial pas-
sage of GFP-B. subtilis transformants from 4th instar 
larvae to the emergent sand fly stage, thereby gener-
ating the first paratransgenic sand fly (Figure 4)[63].  
These results suggest that this deployment strategy 
can be a viable option for field delivery of trans-
formed, non-pathogenic commensal bacteria to sand 
fly breeding sites.  We are currently evaluating several 
molecules, including AMP’s and scFv’s, for an-
ti-leishmania activity for ultimate field use.   
 
 
 
Figure 3: Paratransgenic strategy for control of leishmaniasis.  In this scheme, we propose to transform sand fly commensal 
bacteria to express anti-leishmania molecules (1), these genetically altered microbes will be introduced to sand fly breeding 
sites (2) where they will be consumed by sand fly larvae (3).  We have demonstrated that the genetically altered bacteria will 
be retained by the sand fly as it undergoes metamorphosis (4).  Expression of the anti-leishmania molecule in the gut of the 
emergent paratransgenic sand fly (5) would kill invading leishmania species, therefore rendering the sand fly refractory to 
infection (6), and thus transmission of the parasite. 
 
 
Figure 4: Whole mount of paratransgenic sand fly. A: shows the auto-fluorescence associated with the outer carapace and 
specific GFP fluorescence within the sand fly. B: shows GFP-specific fluorescence signal uncoupled from the background.  
These 4x-images were captures using a Nuance multispectral imaging system.  GFP-specific fluorescence is contained to the 
midgut chamber of the adult sand fly with no evidence of transfer to other regions of the insect. Figure is adapted from 
Hurwitz et al, The paratransgenic sand fly: a platform for control of Leishmania transmission. Parasit Vectors, 2011, 4:e82 
Int. J. Biol. Sci. 2011, 7 
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Conclusions 
Despite great advances in public health world-
wide, insect-transmitted infectious diseases remain a 
leading cause of morbidity and mortality. Currently, 
the best methods for control of many insect-borne 
diseases involve the use of chemical pesticides. 
Though such campaigns may, in the short term, yield 
spectacular results, environmental toxicity and ad-
verse effects on human health limit the use of many 
chemical pesticides. Further, the emergence of insect 
resistance to a wide variety of insecticides has greatly 
undermined their efficacy. Finally, the cost of re-
peated applications of pesticides is often prohibitive. 
We describe a novel method, termed paratransgen-
esis, for transmission control of two specific vector 
borne diseases, Chagas disease and visceral leish-
maniasis, via expression of gene products in the insect 
vectors via transformed symbiotic or commensal mi-
crobes.   We show that the expression of AMP’s can 
significantly reduce carriage of T. cruzi in the hindgut 
of triatomine bugs.  We have recently added other 
molecules, such as endoglucanases and highly specific 
scFv’s, to our armamentarium of effector molecules 
for the paratransgenic control of T. cruzi transmission. 
Effector molecules that may be effective against 
leishmania are currently being studied.  
Unlike current arthropod eradication strategies 
with insecticides, the paratransgenic approach does 
not aim to eliminate triatomine bugs or sand flies.  
Rather, the overarching goal is to modulate the in-
sect’s ability to transmit a parasite. Such an approach 
could provide valuable tools for control of Chagas 
disease and VL in highly endemic regions of the 
world. 
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